Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q1 2025 value amounting to $153000.0.

  • Arcutis Biotherapeutics' Depreciation and Depletion fell 1000.0% to $153000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $623000.0, marking a year-over-year decrease of 2163.52%. This contributed to the annual value of $640000.0 for FY2024, which is 2000.0% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Depreciation and Depletion stood at $153000.0 for Q1 2025, which was down 1000.0% from $145000.0 recorded in Q4 2024.
  • In the past 5 years, Arcutis Biotherapeutics' Depreciation and Depletion ranged from a high of $227000.0 in Q4 2023 and a low of $98000.0 during Q1 2021
  • In the last 5 years, Arcutis Biotherapeutics' Depreciation and Depletion had a median value of $160000.0 in 2022 and averaged $159705.9.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Depreciation and Depletion skyrocketed by 42000.0% in 2021, and later tumbled by 3612.33% in 2024.
  • Arcutis Biotherapeutics' Depreciation and Depletion (Quarter) stood at $182000.0 in 2021, then fell by 12.09% to $160000.0 in 2022, then skyrocketed by 41.88% to $227000.0 in 2023, then tumbled by 36.12% to $145000.0 in 2024, then grew by 5.52% to $153000.0 in 2025.
  • Its Depreciation and Depletion stands at $153000.0 for Q1 2025, versus $145000.0 for Q4 2024 and $161000.0 for Q3 2024.